Voydeya Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Danicopan

Indications/Uses

Add-on to ravulizumab or eculizumab for adult patients w/ paroxysmal nocturnal haemoglobinuria who have residual haemolytic anaemia.

Dosage/Direction for Use

Initially 150 mg tds, approx 8 hr apart (±2 hr). May increase to 200 mg tds after a min of 4 wk of treatment depending on clinical response. Severe renal impairment (eGFR <30 mL/min/1.73 m²) Initially 100 mg tds, approx 8 hr apart (±2 hr). May increase to 150 mg tds after a min of 4 wk of treatment depending on clinical response.

Administration

Should be taken with food.

Contraindications

Hypersensitivity. Patients w/ unresolved Neisseria meningitidis infection at treatment initiation. Patients who are not currently vaccinated against Neisseria meningitidis unless they receive prophylactic treatment w/ appropriate antibiotics until 2 wk after vaccination.

MIMS Class

Immunosuppressants

ATC Classification

L04AJ09 - danicopan ; Belongs to the class of complement inhibitors. Used as immunosuppressants.

Regulatory Classification

POM

Presentation/Packing

Form

Voydeya FC tab 100 mg

Packing/Price

1's

Form

Voydeya FC tab 50 mg

Packing/Price

1's

Voydeya

Manufacturer:

Catalent CTS